GMP Regulatory Newsletter: Summary Scan | Week of 4/29/18

/, CGMP, FDA Enforcement News, Medical Devices/GMP Regulatory Newsletter: Summary Scan | Week of 4/29/18

GMP Regulatory Newsletter: Summary Scan | Week of 4/29/18

By | 2018-05-08T13:19:00+00:00 May 8th, 2018|Biopharma / Pharma, CGMP, FDA Enforcement News, Medical Devices|

Laws, Regulations, Guidance, and Concept Papers

Guidance documents were in modest supply this week:

  • 4 from FDA
  • 4 from EMA
  • 2 from Health Canada
  • 2 items from Pakistan
  • FDA also withdrew 1 final rule due to “significant adverse comments” received during the comment period ending April 11th 2018. This one is important.

To see the complete list of laws, regulations, guidance, and concept papers published this week, start your FREE GMP Regulatory Intelligence Trial today.

In the non-guidance area, we have the usual collection from the US, MHRA, and EMA. The EMA 2017 Annual Report addresses a dramatic decrease in the number of inspections based on the MRA that is now in place with the US. Thus, EMA inspectors have been coming to fewer sites in the US where the FDA routinely inspects.

Enforcement

Enforcement this week was light:

  • 1 letter to a compounding pharmacy
  • Several recalls
  • A few import alerts
  • A form-483 recently issued to Suven Life Sciences Limited
  • Czech authorities issued a report of GDP non-compliance

Seventeen (17) of thirty-seven (37) warning letters have been issued to OTC manufacturers so far this year. This represents 46% of warning letters for the year. OTC manufacturers have replaced the compounding pharmacies in terms of FDA’s warning letter issuance so far.

Learn more about how FDAzilla can help you achieve your quality and inspection preparation goals: get 483sInspector ProfilesEnforcement Analytics, and GMP Regulatory Intelligence. Contact us if you ever have questions at sales@fdazilla.com.

Sign up for your risk-free trial of the leading GMP intelligence newsletter.

About the Author

Barbara W. Unger

Barbara W. Unger formed Unger Consulting, Inc. in December 2014 to provide GMP Quality consulting services to the pharmaceutical and biopharmaceutical industry. At Amgen, she led the segment of the Corporate GMP Audit group at Amgen focused on API manufacturers, Quality Systems and Computers. She developed, implemented and maintained the GMP Regulatory Intelligence program for 8 years at Amgen Inc. This included surveillance, analysis and communication of GMP related legislation, regulations, guidance and industry compliance enforcement trends. This was an essential service and tool within the Corporate Audit function.

Unger Consulting Inc. | www.ungerconsulting.net | 805.217.9360

Leave A Comment